PL1685849T3 - Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego - Google Patents
Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowegoInfo
- Publication number
- PL1685849T3 PL1685849T3 PL04799810T PL04799810T PL1685849T3 PL 1685849 T3 PL1685849 T3 PL 1685849T3 PL 04799810 T PL04799810 T PL 04799810T PL 04799810 T PL04799810 T PL 04799810T PL 1685849 T3 PL1685849 T3 PL 1685849T3
- Authority
- PL
- Poland
- Prior art keywords
- pde
- inhibitors
- interstitial cystitis
- treatment
- pelvic pain
- Prior art date
Links
- 208000005615 Interstitial Cystitis Diseases 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 208000000450 Pelvic Pain Diseases 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229950001653 cilomilast Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000007094 prostatitis Diseases 0.000 abstract 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002586 roflumilast Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003390137 | 2003-11-20 | ||
| EP04799810A EP1685849B1 (en) | 2003-11-20 | 2004-11-18 | Pde 4 inhibitors for the treatment of interstitial cystitis |
| PCT/JP2004/017521 WO2005049087A1 (ja) | 2003-11-20 | 2004-11-18 | 慢性骨盤痛症候群治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1685849T3 true PL1685849T3 (pl) | 2012-07-31 |
Family
ID=34616327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04799810T PL1685849T3 (pl) | 2003-11-20 | 2004-11-18 | Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070167450A1 (pl) |
| EP (1) | EP1685849B1 (pl) |
| JP (1) | JPWO2005049087A1 (pl) |
| AT (1) | ATE542546T1 (pl) |
| CA (1) | CA2544322C (pl) |
| ES (1) | ES2378374T3 (pl) |
| PL (1) | PL1685849T3 (pl) |
| PT (1) | PT1685849E (pl) |
| WO (1) | WO2005049087A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0616633A2 (pt) * | 2005-09-29 | 2011-06-28 | Bayer Healthcare Ag | inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos |
| CA2711865A1 (en) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | A pathological animal model simultaneously developing testicular pain or discomfort behaviors and urinary frequency |
| WO2012062925A2 (en) * | 2010-11-11 | 2012-05-18 | Akron Molecules Gmbh | Compounds and methods for treating pain |
| WO2013155123A1 (en) * | 2012-04-10 | 2013-10-17 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of cyld |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2165192C (en) * | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
| HUT76980A (hu) * | 1994-08-29 | 1998-01-28 | Yamanouchi Pharmaceutical Co. Ltd. | Új naftiridinszármazékok és ezeket a vegyületeket tartalmazó gyógyászati készítmények |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| JPH11292878A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| JPH11292877A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | １，４−ジ置換ピリドピラジン誘導体 |
| WO1999057303A1 (en) | 1998-05-07 | 1999-11-11 | University Of Maryland, Baltimore | A method for diagnosing and treating chronic pelvic pain syndrome |
| AR029185A1 (es) | 1999-10-25 | 2003-06-18 | Yamanouchi Pharma Co Ltd | Derivado de naftiridina |
| GB0011802D0 (en) | 2000-05-16 | 2000-07-05 | Smithkline Beecham | Method for enhancing cognitive function |
| EP1161949A1 (en) | 2000-06-09 | 2001-12-12 | Warner-Lambert Company | Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease |
| WO2002069906A2 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| MXPA03011629A (es) | 2001-06-15 | 2004-07-01 | Yamanouchi Pharmaceuticals Co | Derivado de fenilpiridincarbonilpiperazina. |
| US7101847B2 (en) * | 2002-10-11 | 2006-09-05 | Milkhaus Laboratory, Inc. | Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin |
-
2004
- 2004-11-18 ES ES04799810T patent/ES2378374T3/es active Active
- 2004-11-18 EP EP04799810A patent/EP1685849B1/en not_active Not-in-force
- 2004-11-18 CA CA2544322A patent/CA2544322C/en not_active Expired - Fee Related
- 2004-11-18 US US10/580,417 patent/US20070167450A1/en not_active Abandoned
- 2004-11-18 WO PCT/JP2004/017521 patent/WO2005049087A1/ja not_active Application Discontinuation
- 2004-11-18 PT PT04799810T patent/PT1685849E/pt unknown
- 2004-11-18 AT AT04799810T patent/ATE542546T1/de active
- 2004-11-18 PL PL04799810T patent/PL1685849T3/pl unknown
- 2004-11-18 JP JP2005515691A patent/JPWO2005049087A1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1685849A4 (en) | 2008-12-31 |
| EP1685849A1 (en) | 2006-08-02 |
| ES2378374T3 (es) | 2012-04-11 |
| WO2005049087A1 (ja) | 2005-06-02 |
| CA2544322C (en) | 2012-05-08 |
| US20070167450A1 (en) | 2007-07-19 |
| PT1685849E (pt) | 2012-02-15 |
| JPWO2005049087A1 (ja) | 2007-06-07 |
| EP1685849B1 (en) | 2012-01-25 |
| CA2544322A1 (en) | 2005-06-02 |
| ATE542546T1 (de) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002321105A1 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
| EP1596854A4 (en) | TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE | |
| DE122007000056I1 (de) | Beta-amino-tetrahydroimidazo (1,2-A)pyrazine und-tetrahydrotriazolo(4,3-A)pyrazine als dipeptidyl peptidase Inhibitoren zur Behandlung oder preventionvon Diabetes | |
| HK1062440A1 (en) | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors | |
| PL1983000T3 (pl) | Sposób leczenia stwardnienia rozsianego przez hamowanie aktywności IL-17 | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| HK1155944A1 (en) | W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | |
| DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
| NO20034056L (no) | Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer | |
| ATE465756T1 (de) | Antitumoreffekt-verstärker | |
| PT1470120E (pt) | Derivados n-óxidos de n-fenil-2-pirimidino-amina | |
| WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| ITTO20021024A1 (it) | Trattamento di superficie per componenti ferrosi. | |
| MXPA04007391A (es) | Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes. | |
| PL368271A1 (pl) | Sposób leczenia i zapobiegania bólowi i zapaleniuglukozaminą i inhibitorem selektywnym cyklooksygenazy-2 i kompozycje je zawierające | |
| NO20062229L (no) | Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er) | |
| PL1685849T3 (pl) | Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego | |
| WO2004110373A3 (en) | Therapeutic vaccine compositions for the treatment of type 1 diabetes | |
| EE200300213A (et) | SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks | |
| WO2002039958A3 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| WO2003053365A3 (en) | Syn3 compositions and methods | |
| ZA200308172B (en) | Use of IL-18 inhibitors for treating or preventing CNS injuries. | |
| WO2001044235A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| EP1300159A4 (en) | REMEDIES FOR CANCER | |
| TW200508196A (en) | Hydroxamic acids useful in the treatment of hyper-proliferative disorders |